Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1037/h0037464 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Associations between paraoxonase-1 activity and therapeutic drug monitoring indicators in schizophrenia patients treated with olanzapine: A cross-sectional study.
J Psychopharmacol
January 2025
Psychiatric Research Center, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
Objective: Therapeutic drug monitoring (TDM) indicators have been suggested to predict overall outcome responses to olanzapine (OLZ) treatments in terms of efficacy and metabolic syndrome. This study aimed to investigate whether paraoxonase-1 (PON-1) activity can be used to predict schizophrenia patient outcomes.
Methods: Schizophrenic patients ( = 50) aged between 20 and 65 years who received OLZ treatment were recruited, and their Positive and Negative Syndrome Scale scores, PON-1 activity, and olanzapine drug levels normalized by dose (OLZ/D) and its metabolite N-desmethyl-olanzapine (DMO), together with biochemical parameters, were determined.
Diagnosis of Schizophrenia and Its Subtypes Using MRI and Machine Learning.
Brain Behav
January 2025
Computational and Artificial Intelligence Department, Institute of Cognitive Science Studies, Tehran, Iran.
Purpose: The neurobiological heterogeneity present in schizophrenia remains poorly understood. This likely contributes to the limited success of existing treatments and the observed variability in treatment responses. Our objective was to employ magnetic resonance imaging (MRI) and machine learning (ML) algorithms to improve the classification of schizophrenia and its subtypes.
View Article and Find Full Text PDFMachine learning prediction model of the treatment response in schizophrenia reveals the importance of metabolic and subjective characteristics.
Schizophr Res
January 2025
Department of Psychiatry, Seoul National University Hospital, Seoul, Republic of Korea; Department of Psychiatry, Seoul National University College of Medicine, Seoul, Republic of Korea. Electronic address:
Predicting early treatment response in schizophrenia is pivotal for selecting the best therapeutic approach. Utilizing machine learning (ML) technique, we aimed to formulate a model predicting antipsychotic treatment outcomes. Data were obtained from 299 patients with schizophrenia from three multicenter, open-label, non-comparative clinical trials.
View Article and Find Full Text PDFGlial Derived Neurotrophic Factor and Schizophrenia Spectrum Disorders: A Scoping Review.
Curr Neuropharmacol
December 2024
Ospedale San Luigi Gonzaga, Università degli Studi di Torino, Italia; Regione Gonzole, 10, Orbassano 10043, Torino, Italia.
Background: Psychotic disorders, characterized by altered brain function, significantly impair reality perception. The neurodevelopmental hypothesis suggests these disorders originate from early brain development disruptions. Glial-derived neurotrophic factor (GDNF) is crucial for neuronal survival and differentiation, especially in dopaminergic neurons, and shows promise in neurodegenerative and neuropsychiatric conditions.
View Article and Find Full Text PDFCrocus sativus (saffron) adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled trial.
Int Clin Psychopharmacol
December 2024
Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences.
Current treatments for schizophrenia encounter resistance, limited efficacy, and limiting complications, necessitating novel approaches. The effects of saffron on negative symptoms were investigated as it has shown neuroprotective and antipsychotic properties. Fifty-six clinically stable chronic schizophrenic outpatients were equally assigned to saffron 15 mg q12hr or placebo groups while continuing risperidone.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!